OB/GYN Student Study Guide
Nadroparin was first TGA registered on 14 August 1995, with the higher concentration formulation registered on 3 December 1998. The TGA-approved indications for the lower concentration formulation (Fraxiparine®) are prophylaxis against DVT associated with general or orthopaedic surgery, treatment of DVT and prevention of clotting during haemodialysis. ................
................
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.